ArticleNature communications2025
Stabilizing dual-phased perovskite towards high performance photovoltaics with enhanced batch stability and consistency.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Surface-confined protection stabilizes pre-annealing crystallization for ambient blade-coated perovskites.Nature communications · 2026Article
- Deprotonation suppressing via competitive proton transfer control for efficient perovskite solar cells.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fabricating high-performance perovskite solar cells (PSCs) with solution processing is conducive to low-cost commercial production, it is therefore rather critical to stabilize perovskite in both solution and solid phases. For this purpose, the speed-up ageing of perovskite solution in air was systematically studied and its severe spontaneous degradation was observed. To address this issue, we introduce 4-(trifluoromethyl) phenylhydrazine (TFPH) to modify the perovskite solution, which presents enhanced storage stability. Consequently, when the modified solution was used to prepare PSCs, we obtained much improved and well consistent power conversion efficiencies (PCEs, ~ 26.0%) regardless of the perovskite solution ageing time, as well as exciting operational stability, which maintains PCE ≥ 92% for 1830 hours. These results are attributed to TFPH's multifunctionality: a) hydrazine groups inhibit perovskite decomposition by dual-pathway mechanism; b) trifluoromethyl boosts dipole moment, aiding crystallization and strain relaxation; c) impurity reduction and high-quality film jointly lower charge traps. This work substantially assists understanding and modifying perovskite degradation in both solution and solid phases. The developed performance stability and consistency on the TFPH modified device batches is of great significance for commercial production of PSCs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.